European Union regulators on Wednesday fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory approval.
The fine from the European Commission, the EU's executive body, amounts to 10% of San Diego-based Illumina's turnover.
The Illumina fine exceeds the commission's previous largest merger regulation fine of $125 million, or 1% of annual turnover, imposed on telecommunications company Altice in 2018.
Illumina has already put aside $453 million to cover a potential maximum fine of 10% of turnover, according to a regulatory filing from earlier this year.
"This is a very serious infringement, which requires the imposition of a proportionate fine, with the aim of deterring such conduct," the European Commission continued.
Persons:
Illumina
Organizations:
European Commission, EU, Altice
Locations:
San Diego, Menlo Park , California